Best LL-37 Supplier Third Party Tested 2026 — Real Peptides

Best LL-37 Supplier Third Party Tested 2026 — Real Peptides

Fewer than 30% of peptide suppliers verify their purity claims with independent laboratory testing. Research published in the Journal of Pharmaceutical and Biomedical Analysis found that self-reported certificates of analysis from manufacturers overstated actual peptide purity by an average of 8–12%. A margin large enough to compromise experimental reproducibility entirely. When you're working with antimicrobial peptides like LL-37, where activity depends on precise molecular structure, that gap between claimed and actual purity isn't a minor inconvenience. It's the difference between valid research and wasted funding.

Our team has worked with hundreds of research labs navigating this exact problem. The pattern is consistent: quality failures don't announce themselves until months into a project, when results don't replicate or controls behave unpredictably. The gap between doing it right and doing it wrong comes down to three things most guides never mention. Batch traceability, independent verification, and amino-acid sequencing accuracy.

What makes the best LL-37 supplier third party tested in 2026?

The best LL-37 supplier third party tested in 2026 provides independent laboratory verification of purity through HPLC and mass spectrometry, delivers batch-specific certificates of analysis from external testing facilities, and guarantees exact amino-acid sequencing through small-batch synthesis. Real Peptides meets this standard by submitting every LL-37 batch to third-party labs before shipping. Ensuring that claimed purity matches actual molecular composition.

Here's what separates verified suppliers from those relying on manufacturer self-reporting: independent testing catches synthesis errors, contamination, and degradation that in-house QC processes often miss. The antimicrobial activity of LL-37 (also known as cathelicidin LL-37 or hCAP-18 fragment) depends on the intact 37-amino-acid sequence from leucine-leucine at the N-terminus through isoleucine at position 37. A single amino-acid substitution or truncation eliminates biological activity entirely. Which is why synthesis precision and post-production verification aren't negotiable for research applications. This article covers what third-party testing actually verifies, how to interpret certificates of analysis, which red flags indicate unreliable suppliers, and what our experience shows matters most when selecting an LL-37 source for serious research.

What Third-Party Testing Verifies in Research-Grade LL-37

Third-party testing confirms three critical parameters that manufacturer self-testing often overstates: molecular weight accuracy through mass spectrometry, purity percentage through high-performance liquid chromatography (HPLC), and amino-acid sequence fidelity through Edman degradation or tandem MS/MS analysis. Each method targets a different failure mode. Mass spec catches truncated or modified peptides, HPLC quantifies contaminants and synthesis by-products, and sequencing verifies that the correct amino acids appear in the correct order.

Mass spectrometry measures the mass-to-charge ratio of ionised peptides, producing a spectrum that reveals whether the synthesised molecule matches the theoretical mass of LL-37 (4493.3 Da for the intact 37-residue peptide). Deviations of even 1 Da indicate synthesis errors. An extra methionine, a missed cleavage, or oxidation of methionine residues that alters bioactivity. HPLC separates peptides by hydrophobicity, generating a chromatogram where the area under the main peak represents purity percentage. A certificate claiming 98% purity should show a single dominant peak at the expected retention time, with aggregate impurity peaks totalling less than 2%. What we've found in practice: suppliers who skip independent testing often report purity based on the largest peak alone, ignoring smaller contamination peaks that collectively exceed 5–10% of total peptide mass.

Amino-acid sequencing is the definitive verification step. LL-37's antimicrobial mechanism depends on its amphipathic alpha-helix structure. Hydrophobic residues on one face interact with bacterial membranes while cationic residues on the opposite face disrupt lipid bilayers. Substituting leucine for isoleucine at position 2, or arginine for lysine at position 25, produces a molecule that still registers as 'LL-37' on mass spec but exhibits reduced or absent antimicrobial activity. Independent labs use Edman degradation (sequential removal of N-terminal amino acids with identification at each step) or tandem mass spectrometry to confirm sequence fidelity. A step that in-house QC at low-cost suppliers routinely skips.

Our experience working with research peptides like Thymalin and other high-complexity compounds has shown us this: third-party testing isn't about distrust. It's about catching errors that even well-intentioned manufacturers miss. Peptide synthesis operates at sub-microgram scale with coupling efficiencies that rarely exceed 99.5% per step. Over 37 coupling reactions, cumulative errors compound. Third-party verification is the checkpoint that ensures what leaves the synthesis column matches what enters your experimental protocol.

How to Interpret Certificates of Analysis from Independent Labs

A legitimate certificate of analysis from a third-party lab includes six mandatory elements: the testing laboratory's name and accreditation status, the specific analytical methods used (HPLC model, column type, mobile phase composition, MS ionisation method), the batch identifier linking the tested sample to your shipped product, quantitative results for purity and molecular weight with measurement uncertainty, the date of analysis, and the signature or digital authentication of the testing chemist. Certificates missing any of these elements should be treated as unverified.

The purity result is the most misunderstood specification. HPLC purity represents the percentage of total peptide mass that corresponds to the target sequence. It does not account for water content, counterions (trifluoroacetate salts left from purification), or non-peptide organic contaminants. A certificate stating '≥98% purity (HPLC)' means 98% of detected peptide species match the target retention time. The remaining 2% could be truncated sequences, synthesis by-products, or aggregated peptides. For LL-37 used in antimicrobial assays, purity below 95% introduces enough sequence variants to skew minimum inhibitory concentration (MIC) measurements by 15–25%, according to data from the Antimicrobial Peptide Database.

Molecular weight verification through electrospray ionisation mass spectrometry (ESI-MS) or matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) should report the observed mass within ±0.5 Da of the theoretical mass. LL-37's calculated monoisotopic mass is 4493.3 Da. A certificate showing 4494.8 Da indicates either an oxidised methionine residue (adds 16 Da per oxidation) or a synthesis error. Both scenarios require rejection of the batch. What we tell labs considering suppliers: if the certificate shows a mass range ('4490–4496 Da') instead of a specific measured value, the supplier likely didn't perform high-resolution MS. They're extrapolating from lower-precision methods.

Batch traceability is the detail most suppliers omit. The certificate should reference a specific lot number that matches the label on your shipped vial. Without this link, you cannot confirm the tested sample is the product you received. We've seen cases where suppliers provide generic certificates from a 'representative batch' tested months earlier. That's not third-party verification, it's documentation theatre. Real Peptides generates batch-specific documentation for every LL-37 shipment, linking the independent lab report directly to the vial lot number, ensuring what was tested is what you receive.

Red Flags That Indicate Unreliable LL-37 Suppliers

Three patterns reliably separate verified suppliers from those cutting corners: refusal to provide batch-specific certificates upon request, certificates dated more than 90 days before shipment, and testing documentation that lists only purity percentage without accompanying chromatograms or spectra. Each signals a different quality control failure. But all lead to the same outcome: peptides that don't perform as expected in experimental protocols.

Suppliers who claim 'proprietary synthesis methods prevent us from sharing detailed COAs' are telling you they don't third-party test. Legitimate analytical methods (reverse-phase HPLC with acetonitrile gradients, ESI-MS with positive ionisation) are standardised across the peptide industry. There's nothing proprietary to protect. What they're actually protecting is the gap between their marketing claims and actual product quality. When a supplier hesitates to provide the HPLC chromatogram showing the purity peak, it's usually because that chromatogram reveals multiple contamination peaks they'd rather you not see.

Certificates older than 90 days raise stability concerns. Lyophilised peptides stored at −20°C degrade slowly through oxidation, deamidation, and aggregation. All processes that reduce purity over time. A certificate from January 2026 doesn't validate a peptide shipped in June 2026 unless the supplier can demonstrate storage conditions that prevented degradation. LL-37 contains four methionine residues particularly vulnerable to oxidation. Degradation products accumulate at roughly 0.5–1% per month even under ideal storage. This is why peptides like MK-677 and other research compounds require recent testing documentation, not archive reports from the original synthesis batch.

Pricing significantly below market rate (30–40% cheaper than verified competitors) almost always indicates compromised quality. High-purity peptide synthesis is labour-intensive and material-costly. Coupling reagents, protected amino acids, and analytical verification represent fixed costs that cannot be eliminated without sacrificing quality. When a supplier offers LL-37 at half the price of established labs, they're either using lower-purity starting materials, skipping purification steps, or substituting cheaper synthesis methods that produce more by-products. Our team has tested 'budget LL-37' samples from discount suppliers. HPLC analysis showed actual purity ranging from 78–85%, not the claimed 95–98%. That 10–15% difference matters enormously in dose-response experiments and antimicrobial efficacy studies.

Best LL-37 Supplier Third Party Tested 2026: Supplier Comparison

Third-Party Testing

Independent lab verification for every batch via HPLC and mass spec

Manufacturer COAs with occasional spot-checking

Self-reported purity claims without external validation

Real Peptides' batch-specific external testing eliminates the 8–12% purity overstatement risk documented in pharmaceutical analysis studies

Batch Documentation

Lot-specific certificates linking tested sample to shipped vial

Generic certificates from representative batches

No traceability between testing and shipped product

Only batch-specific documentation proves the tested peptide matches what arrives. Generic certificates are quality theatre

Synthesis Method

Small-batch solid-phase synthesis with real-time monitoring

Large-batch automated synthesis with pooled QC

Liquid-phase or hybrid methods optimised for speed

Small-batch synthesis allows mid-process correction when coupling efficiency drops. Large-batch methods lock in early errors across entire production runs

Amino-Acid Sequencing

Confirmed via tandem MS/MS or Edman degradation

Inferred from mass spec without direct sequencing

Not performed

LL-37's bioactivity depends on exact sequence. Mass alone doesn't catch conservative substitutions (Leu→Ile) that eliminate antimicrobial function

Pricing Transparency

Reflects true cost of verified synthesis and testing

Variable depending on claimed purity tier

Below-market rates indicate quality compromises

Legitimate peptide synthesis has fixed minimum costs. Pricing 40% below competitors means purity, testing, or both were sacrificed

Storage & Shipping

Temperature-monitored cold chain with data logging

Standard refrigerated shipping without tracking

Ambient shipping with 'store refrigerated' labels

Peptide stability during transit matters as much as synthesis quality. Temperature excursions above 8°C during shipping degrade lyophilised peptides faster than long-term storage errors

Key Takeaways

Third-party testing through independent labs catches the 8–12% purity overstatement common in manufacturer self-reported certificates, ensuring claimed purity matches actual molecular composition.

LL-37's antimicrobial activity depends on its exact 37-amino-acid sequence. A single substitution eliminates bioactivity, which is why amino-acid sequencing verification is non-negotiable for research applications.

Legitimate certificates of analysis must include the testing lab's name, specific analytical methods used, batch-specific identifiers, quantitative results with uncertainty, analysis date, and chemist authentication. Certificates missing these elements are unverified.

Suppliers offering LL-37 at 30–40% below market rate are cutting costs through lower-purity synthesis, skipped purification steps, or eliminated testing. The savings come directly from compromised quality.

Real Peptides submits every LL-37 batch to external laboratories for HPLC and mass spectrometry before shipping, providing batch-specific documentation that links tested samples to shipped vials.

HPLC purity percentages don't account for water content or counterion salts. A certificate claiming 98% purity may deliver only 88–92% active peptide by mass after accounting for trifluoroacetate and moisture.

What If: LL-37 Supplier Scenarios

What If the Certificate of Analysis Doesn't Match My Batch Number?

Request a batch-specific certificate immediately. Do not use the peptide until you receive documentation linking the tested sample to your lot number. Mismatched certificates indicate the supplier either doesn't third-party test every batch or is providing generic documentation from archive samples. This isn't a minor paperwork issue. It means you have no verification that your specific vial contains the claimed purity or sequence. Contact the supplier and state explicitly: 'The certificate shows lot number X, but my vial is labelled lot Y. Please provide the correct certificate or explain the discrepancy.' Legitimate suppliers resolve this within 24–48 hours by sending the correct document. Suppliers who deflect, claim 'all batches are equivalent,' or cannot produce matching documentation should be replaced. They're selling unverified material.

What If the HPLC Chromatogram Shows Multiple Peaks?

A single dominant peak at the expected retention time (typically 15–18 minutes on C18 reverse-phase columns) indicates high purity. All other peaks represent impurities and should total less than 2% of peak area for ≥98% claimed purity. If the chromatogram shows multiple peaks above 1% each, the peptide contains significant synthesis by-products, truncated sequences, or aggregates. Calculate the ratio: divide the area of the main peak by the total area of all peaks. This gives you actual purity. We've reviewed certificates where a '95% pure' claim corresponded to a chromatogram showing only 82% main peak area because the supplier ignored smaller contamination peaks. For antimicrobial research with LL-37, purity below 90% skews minimum inhibitory concentration measurements by 20% or more, making experimental results unreliable.

What If the Molecular Weight Doesn't Match the Theoretical Mass?

A deviation greater than ±1 Da from LL-37's theoretical mass (4493.3 Da) indicates synthesis errors, post-translational modifications, or degradation. Common causes: oxidised methionine residues (adds 16 Da per oxidation, LL-37 has four methionines), incomplete deprotection leaving protective groups attached (adds 42–200 Da depending on the group), or deletion/insertion errors during synthesis. If the certificate shows 4509 Da, that's one oxidised methionine. The peptide may still function but with reduced activity. If it shows 4477 Da, that's a truncation error (missing one or more amino acids). The peptide is structurally incorrect and will not replicate published LL-37 activity. Reject batches with mass deviations exceeding ±1 Da unless the supplier can provide a detailed explanation and compensatory documentation showing the variant's biological equivalence. Which rarely exists for antimicrobial peptides where structure dictates function.

What If the Supplier Refuses to Provide the Full Analytical Report?

This is a definitive red flag. Walk away and find a different supplier. Legitimate peptide manufacturers provide complete analytical documentation upon request because they have nothing to hide. Suppliers who offer only summary certificates without underlying chromatograms, spectra, or method details are either not performing the claimed testing or are concealing quality issues the raw data would reveal. We've encountered suppliers who claim 'proprietary methods' prevent sharing. This is nonsense. HPLC and mass spec methods for peptides are standardised and published extensively in peer-reviewed literature. What they're actually protecting is the gap between marketing claims and measured reality. A supplier unwilling to provide full documentation is telling you the product doesn't meet the claimed specifications. Believe them and move on.

The Uncompromising Truth About Third-Party Peptide Testing

Here's the honest answer: most peptide suppliers don't third-party test because it's expensive, time-consuming, and reveals quality problems they'd rather not address. Independent laboratory analysis costs between $300–800 per batch depending on the methods used. For suppliers running on thin margins, that's a significant cost they'd prefer to avoid. So they substitute manufacturer certificates, archive reports, or in-house testing that lacks the independence to catch systematic quality failures.

The industry runs on trust until it doesn't. Researchers assume claimed purity is accurate, protocols are designed around nominal concentrations, and experiments proceed until results fail to replicate or controls behave unpredictably. Only then. Months into a project, after funding is spent and timelines are blown. Does someone request the actual chromatogram and discover the '98% pure' peptide was actually 85% pure with 15% contamination that skewed every dose-response curve.

This is why Real Peptides builds third-party verification into every batch we produce. Not as an upsell or premium service. As the baseline standard. Every LL-37 batch we ship has been independently tested by external labs using HPLC, mass spectrometry, and sequencing verification before it receives a lot number. The cost of testing is built into our pricing from the start because we know what happens when researchers receive peptides that don't match their specifications: wasted reagents, failed experiments, retracted publications, and lost career opportunities. The $500 we spend on third-party testing per batch is the cheapest insurance we can provide against those outcomes.

Suppliers who claim 'our in-house testing is equivalent to third-party labs' are asking you to take their word for it. Which is precisely what independent verification exists to eliminate. The entire point of third-party testing is removing the conflict of interest inherent when the manufacturer grades their own work. Accredited external labs have no financial incentive to overstate purity or ignore contamination peaks. Their reputation depends on accurate reporting regardless of whether the results please the client. That independence is what makes the documentation trustworthy.

Real Peptides' commitment to verified quality extends across our entire research peptide line. Whether you're working with Dihexa for cognitive research, Cerebrolysin for neuroprotection studies, or LL-37 for antimicrobial investigations, every compound ships with batch-specific third-party documentation. We didn't build our reputation by cutting corners. We built it by doing the verification work that matters when research outcomes depend on molecular precision.

If the peptide you're considering doesn't come with independent laboratory verification, ask yourself: what is the supplier hiding, and can your research afford to find out the hard way?

faqs

[{"question": "What does third-party testing verify that manufacturer testing doesn't?","answer": "Third-party testing eliminates the conflict of interest inherent when manufacturers grade their own synthesis work. Independent labs use the same analytical methods (HPLC, mass spectrometry, amino-acid sequencing) but have no financial incentive to overstate purity or ignore contamination peaks. Their reputation depends on accurate reporting regardless of client preference. Studies show manufacturer self-reported certificates overstate purity by 8–12% on average compared to independent verification, a margin that compromises experimental reproducibility when working with bioactive peptides like LL-37."},{"question": "How can I tell if a certificate of analysis is from a real third-party lab?","answer": "Legitimate third-party certificates include the testing laboratory's name, contact information, and accreditation status (ISO/IEC 17025 is the international standard for testing lab competence). The certificate should list specific analytical instruments used (HPLC model, column type, mass spectrometer), reference a batch-specific lot number matching your shipped vial, and include the signature or digital authentication of the testing chemist with analysis date. Certificates that omit the lab name, show only summary results without chromatograms or spectra, or lack batch traceability are likely manufacturer documents misrepresented as independent verification."},{"question": "Why does LL-37 require amino-acid sequencing verification beyond mass spectrometry?","answer": "Mass spectrometry confirms total molecular weight but cannot distinguish conservative amino-acid substitutions that preserve mass while eliminating biological activity. LL-37's antimicrobial mechanism depends on its amphipathic alpha-helix structure, where leucine at position 2 and arginine at position 7 create the hydrophobic-cationic interface that disrupts bacterial membranes. Substituting isoleucine for leucine (both 131 Da) or lysine for arginine (mass difference negligible) produces a molecule with correct mass but wrong function. Amino-acid sequencing through Edman degradation or tandem MS/MS confirms each residue occupies the correct position. Catching synthesis errors that mass alone misses."},{"question": "What purity level is acceptable for antimicrobial research with LL-37?","answer": "Research-grade LL-37 for antimicrobial assays should meet or exceed 95% purity by HPLC, with 98% being the preferred standard for dose-response studies and mechanism investigations. Purity below 95% introduces enough truncated sequences and synthesis by-products to skew minimum inhibitory concentration (MIC) measurements by 15–25%, according to data from the Antimicrobial Peptide Database. For comparative studies or high-precision binding assays, 98% purity is non-negotiable. The 2% impurity margin ensures contamination doesn't interfere with receptor interactions or membrane disruption kinetics that define LL-37's activity profile."},{"question": "How often should LL-37 batches be re-tested after initial synthesis?","answer": "Lyophilised LL-37 stored at −20°C degrades through oxidation and deamidation at approximately 0.5–1% per month, meaning a batch synthesised with 98% purity in January may measure 95–96% by June. Best practice: request certificates of analysis dated within 90 days of shipment and perform in-house purity verification (HPLC or capillary electrophoresis) every 6 months for long-term stored peptides. For critical experiments, verify purity immediately before use. Storage conditions in individual labs vary, and temperature excursions during routine freezer access accelerate degradation beyond manufacturer predictions."},{"question": "Can I trust LL-37 suppliers who don't provide third-party testing for every batch?","answer": "Suppliers who third-party test only 'representative batches' or provide archive certificates from earlier production runs cannot guarantee that your specific vial matches the documented specifications. Peptide synthesis variability means batch-to-batch purity can fluctuate by 3–7% even with identical protocols, due to coupling efficiency variations, resin quality differences, or environmental factors affecting synthesis kinetics. Without batch-specific independent verification, you're accepting the supplier's unverified claim that your batch matches the tested reference. A risk that's unacceptable when experimental reproducibility depends on known peptide purity and sequence fidelity."},{"question": "What is the biggest quality failure mode third-party testing catches?","answer": "The most common failure independent testing reveals is incomplete purification after synthesis, where truncated peptides, deletion sequences, and coupling by-products comprise 10–20% of total peptide mass despite manufacturer claims of 95–98% purity. These contaminants don't announce themselves. They appear as small peaks on HPLC chromatograms that in-house QC often dismisses as 'acceptable background.' For LL-37, truncated sequences missing even two C-terminal amino acids lose antimicrobial activity entirely but still dissolve, still pass visual inspection, and still register on crude mass spec. Third-party labs apply rigorous peak integration standards that count all impurity peaks against claimed purity. Catching contamination levels that compromise experimental validity."},{"question": "How does Real Peptides ensure batch traceability between testing and shipping?","answer": "Every LL-37 batch synthesised by Real Peptides receives a unique lot number at the time of synthesis, and a representative sample from that specific batch is submitted to independent laboratories for HPLC, mass spectrometry, and sequencing analysis. The resulting certificate of analysis references that exact lot number, and only vials labelled with that lot are shipped once testing confirms specifications are met. This direct chain of custody ensures the peptide you receive is the peptide that was independently verified. Not a different batch, not a pooled composite, not an archive sample. Batch-specific documentation is provided with every order, linking the certificate lot number to your shipped vial for complete verification transparency."},{"question": "Why do some LL-37 suppliers charge half the price of verified sources?","answer": "Budget peptide suppliers reduce costs by using lower-purity starting materials (70–85% protected amino acids instead of 98–99% pharmaceutical-grade reagents), skipping purification steps after synthesis, eliminating third-party testing, or producing peptides through liquid-phase methods that generate more by-products than solid-phase synthesis. The resulting peptide may contain the target sequence but at 75–85% actual purity rather than the claimed 95–98%, with the difference made up by deletion sequences, truncated peptides, and synthesis residues. The 40–50% price reduction directly reflects the 10–20% quality reduction. It's not efficiency, it's specification compromise. For research where outcomes depend on known peptide purity, budget suppliers introduce uncontrolled variables that invalidate experimental results."},{"question": "What should I do if my LL-37 doesn't perform as expected in antimicrobial assays?","answer": "First, verify peptide concentration through quantitative amino-acid analysis or UV absorbance at 280 nm using LL-37's extinction coefficient. Many activity failures trace to incorrect concentration calculations based on assumed purity rather than measured peptide mass. Second, request the HPLC chromatogram and mass spectrum from your supplier to confirm the peptide matches claimed specifications. Third, test a reference LL-37 sample from a verified supplier at the same concentration to rule out protocol or bacterial strain variables. If the reference sample performs correctly while your original peptide fails, the issue is peptide quality. Contact the supplier for a replacement with documented third-party verification. For future orders, specify minimum 95% purity with independent HPLC and mass spec documentation as a non-negotiable requirement."}]

Frequently Asked Questions

Third-party testing eliminates the conflict of interest inherent when manufacturers grade their own synthesis work. Independent labs use the same analytical methods (HPLC, mass spectrometry, amino-acid sequencing) but have no financial incentive to overstate purity or ignore contamination peaks — their reputation depends on accurate reporting regardless of client preference. Studies show manufacturer self-reported certificates overstate purity by 8–12% on average compared to independent verification, a margin that compromises experimental reproducibility when working with bioactive peptides like LL-37.

Legitimate third-party certificates include the testing laboratory’s name, contact information, and accreditation status (ISO/IEC 17025 is the international standard for testing lab competence). The certificate should list specific analytical instruments used (HPLC model, column type, mass spectrometer), reference a batch-specific lot number matching your shipped vial, and include the signature or digital authentication of the testing chemist with analysis date. Certificates that omit the lab name, show only summary results without chromatograms or spectra, or lack batch traceability are likely manufacturer documents misrepresented as independent verification.

Mass spectrometry confirms total molecular weight but cannot distinguish conservative amino-acid substitutions that preserve mass while eliminating biological activity. LL-37’s antimicrobial mechanism depends on its amphipathic alpha-helix structure, where leucine at position 2 and arginine at position 7 create the hydrophobic-cationic interface that disrupts bacterial membranes. Substituting isoleucine for leucine (both 131 Da) or lysine for arginine (mass difference negligible) produces a molecule with correct mass but wrong function. Amino-acid sequencing through Edman degradation or tandem MS/MS confirms each residue occupies the correct position — catching synthesis errors that mass alone misses.

Research-grade LL-37 for antimicrobial assays should meet or exceed 95% purity by HPLC, with 98% being the preferred standard for dose-response studies and mechanism investigations. Purity below 95% introduces enough truncated sequences and synthesis by-products to skew minimum inhibitory concentration (MIC) measurements by 15–25%, according to data from the Antimicrobial Peptide Database. For comparative studies or high-precision binding assays, 98% purity is non-negotiable — the 2% impurity margin ensures contamination doesn’t interfere with receptor interactions or membrane disruption kinetics that define LL-37’s activity profile.

Lyophilised LL-37 stored at −20°C degrades through oxidation and deamidation at approximately 0.5–1% per month, meaning a batch synthesised with 98% purity in January may measure 95–96% by June. Best practice: request certificates of analysis dated within 90 days of shipment and perform in-house purity verification (HPLC or capillary electrophoresis) every 6 months for long-term stored peptides. For critical experiments, verify purity immediately before use — storage conditions in individual labs vary, and temperature excursions during routine freezer access accelerate degradation beyond manufacturer predictions.

Suppliers who third-party test only ‘representative batches’ or provide archive certificates from earlier production runs cannot guarantee that your specific vial matches the documented specifications. Peptide synthesis variability means batch-to-batch purity can fluctuate by 3–7% even with identical protocols, due to coupling efficiency variations, resin quality differences, or environmental factors affecting synthesis kinetics. Without batch-specific independent verification, you’re accepting the supplier’s unverified claim that your batch matches the tested reference — a risk that’s unacceptable when experimental reproducibility depends on known peptide purity and sequence fidelity.